Shakeel Modak

16PUBLICATIONS
43CO-AUTHORS
Gene and molecular therapyHaematological tumoursNanotoxicology, health and safetyCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Mar 31, 2026
Low-Dose Intravenous Ketamine for Primary Pain Control During Naxitamab Anti-GD2 Immunotherapy Treatment.

Rosanna Silber, Benjamin Record, Nicole Fernandez

|Feb 11, 2026
A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.

Brian H Kushner, Shakeel Modak, Charlie White

|Jan 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission.

Brian H Kushner, Charlie White, Audrey Mauguen

|Aug 29, 2025
A Single Institutional Experience Using Romiplostim to Treat Therapy-Related Thrombocytopenia in Pediatric Solid Tumor Patients.

Melanie D Degliuomini, Katherine Armstrong, Michael Curry

|Jul 16, 2025
Rapid COJEC without myeloablative therapy for high-risk neuroblastoma.

Brian H Kushner, Ellen M Basu, Fiorella Iglesias Cardenas

|Jul 10, 2025
Clinical Significance of TERT Promoter Mutations in Neuroblastoma.

Natasha Persaud, Gunes Gundem, Brian H Kushner

Pageof 3

Frequent Collaborators

6 joint publications

Brian H Kushner

2 joint publications

Stephen S Roberts

1 joint publications

Pichai Raman

1 joint publications

Karthik Kalletla